225 related articles for article (PubMed ID: 16563504)
1. JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.
Mesa RA; Powell H; Lasho T; Dewald G; McClure R; Tefferi A
Leuk Res; 2006 Nov; 30(11):1457-60. PubMed ID: 16563504
[TBL] [Abstract][Full Text] [Related]
2. Decreased JAK2 V617F allele burden level in a myelofibrosis with myeloid metaplasia patient with leukemic transformation.
Wu YY; Hung HM; Chen TS; Chao TY; Ho CL
Leuk Res; 2008 Nov; 32(11):1783-6. PubMed ID: 18455791
[No Abstract] [Full Text] [Related]
3. Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development.
Ohyashiki K; Kodama A; Ohyashiki JH
Cancer Genet Cytogenet; 2008 Oct; 186(1):6-11. PubMed ID: 18786436
[TBL] [Abstract][Full Text] [Related]
4. Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy.
Tefferi A; Strand JJ; Lasho TL; Elliott MA; Li CY; Mesa RA; Dewald GW
Cancer; 2006 Apr; 106(8):1739-43. PubMed ID: 16532437
[TBL] [Abstract][Full Text] [Related]
5. Analysis of JAK2(V617F) mutation in Chinese patients with myeloproliferative disorders.
Chen S; Fei H; Zhang R; Xue Y; Pan J; Wu Y; Ceng J
Am J Hematol; 2007 Jun; 82(6):458-9. PubMed ID: 17266061
[TBL] [Abstract][Full Text] [Related]
6. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
[TBL] [Abstract][Full Text] [Related]
7. Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
Kreft A; Springer E; Lipka DB; Kirkpatrick CJ
Acta Haematol; 2009; 122(1):36-8. PubMed ID: 19713696
[TBL] [Abstract][Full Text] [Related]
8. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
Passamonti F; Rumi E; Pietra D; Elena C; Boveri E; Arcaini L; Roncoroni E; Astori C; Merli M; Boggi S; Pascutto C; Lazzarino M; Cazzola M
Leukemia; 2010 Sep; 24(9):1574-9. PubMed ID: 20631743
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal study of the JAK2(V617F) mutation in myelofibrosis with myeloid metaplasia: analysis at two time points.
Mesa RA; Powell H; Lasho T; DeWald GW; McClure R; Tefferi A
Haematologica; 2006 Mar; 91(3):415-6. PubMed ID: 16531268
[TBL] [Abstract][Full Text] [Related]
10. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.
Wolanskyj AP; Lasho TL; Schwager SM; McClure RF; Wadleigh M; Lee SJ; Gilliland DG; Tefferi A
Br J Haematol; 2005 Oct; 131(2):208-13. PubMed ID: 16197451
[TBL] [Abstract][Full Text] [Related]
11. Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.
Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H; Bock O
Ann Hematol; 2007 Apr; 86(4):245-53. PubMed ID: 17262192
[TBL] [Abstract][Full Text] [Related]
12. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
[TBL] [Abstract][Full Text] [Related]
13. The decrease of JAK2 V617F allele burden in leukemia transformation of an elderly patient with myelofibrosis.
Zhang SJ; Li JY; Zhang JF; Finn J; Lu H; Xu W; Qian SX; Wu HX
Leuk Res; 2009 Aug; 33(8):e116-8. PubMed ID: 19328546
[No Abstract] [Full Text] [Related]
14. Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
Ruiz-Argüelles GJ; Garcés-Eisele J; Reyes-Núñez V; Ruiz-Delgado GJ; Rosillo C; Camoriano JK
Am J Hematol; 2007 May; 82(5):400-2. PubMed ID: 17133423
[TBL] [Abstract][Full Text] [Related]
15. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
16. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
Poodt J; Fijnheer R; Walsh IB; Hermans MH
Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
[TBL] [Abstract][Full Text] [Related]
17. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
18. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.
Barosi G; Bergamaschi G; Marchetti M; Vannucchi AM; Guglielmelli P; Antonioli E; Massa M; Rosti V; Campanelli R; Villani L; Viarengo G; Gattoni E; Gerli G; Specchia G; Tinelli C; Rambaldi A; Barbui T;
Blood; 2007 Dec; 110(12):4030-6. PubMed ID: 17712047
[TBL] [Abstract][Full Text] [Related]
19. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation.
Steckel NK; Koldehoff M; Ditschkowski M; Beelen DW; Elmaagacli AH
Transplantation; 2007 Jun; 83(11):1518-20. PubMed ID: 17565328
[TBL] [Abstract][Full Text] [Related]
20. [Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera].
Roche-Lestienne C; Andrieux J
Pathol Biol (Paris); 2007 Feb; 55(1):49-55. PubMed ID: 16901657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]